Novo Nordisk ($NOVO B (+0,01 %) ) is back on the hunt for deals to boost its obesity portfolio after losing U.S. biotech Metsera in a bidding war with Pfizer ($PFE (-0,43 %)) late last year, Bloomberg’s Naomi Kresge and Cynthia Koons report. “We’re in the market for big or small,” Chief Executive Officer Mike Doustdar said in an interview at the JPMorgan Healthcare Conference in San Francisco. “As long as it’s complementary to our own assets, then we can go very big, very big in buying something in, but it has to be worth it and it has to be so much better than whatever we have.” Several names in the space were moving up following the news report, including Viking Therapeutics ($VKTX (+1,55 %)), Terns Pharmaceuticals ($TERN), and Structure Therapeutics ($GPCR).